Dr Reddys Laboratories is making waves in the pharmaceutical industry with two significant developments: preparation for generic weight-loss drug ingredients and the launch of a novel molecule for gastrointestinal diseases.

Generic Weight-Loss Drug Ingredients

Dr. Reddy's, along with other Indian pharmaceutical companies, is gearing up to supply key ingredients for generic versions of Novo Nordisk's popular weight-loss medications. These preparations come as the drugs are set to lose patent protection in major markets, opening up opportunities for generic manufacturers to enter this lucrative segment.

The move highlights the Indian pharmaceutical industry's readiness to capitalize on emerging opportunities in the global healthcare market, particularly in the rapidly growing field of weight management medications.

Launch of Novel Molecule Tegoprazan

In a parallel development, Dr. Reddy's has announced the launch of Tegoprazan, a novel patented molecule for the treatment of acid-related gastrointestinal diseases in India. The company is introducing Tegoprazan (50 mg) under the brand name PCAB®.

Tegoprazan is a next-generation potassium-competitive acid blocker, indicated for the treatment of various acid peptic diseases (APD) including:

• Erosive Gastroesophageal Reflux Disease (GERD)
• Non-Erosive Gastroesophageal Reflux Disease (NERD)
• Gastric Ulcer

The launch follows Dr. Reddy's exclusive partnership formed in 2022 with South Korea-based HK inno.N Corporation to commercialize Tegoprazan in India and select emerging markets.

Clinical Efficacy and Market Potential

In a multinational clinical trial conducted by Dr. Reddy's across India, South Africa, and Russia, 99.00% of GERD patients in the Tegoprazan treatment arm achieved endoscopic healing by Week 8. This high efficacy rate underscores the potential of Tegoprazan to address the significant need in APD management, especially considering that APD affects approximately 38.00% of the Indian population.

M.V. Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr. Reddy's, commented on the launch: "We are happy to launch Tegoprazan (PCAB®) in India, reinforcing our commitment to innovation in gastrointestinal diseases treatment – a key focus area for us."

Global Presence and Future Outlook

Tegoprazan is already approved in 21 countries, including South Korea and China, and is currently under registration in several other countries. It has also successfully completed Phase-III trials in the United States, indicating potential for further global expansion.

As Dr. Reddy's continues to strengthen its position in the gastrointestinal therapeutics market with established brands like Omez®, Razo®, and Vono™, the addition of Tegoprazan to its portfolio is expected to enhance patient access to innovative treatments for acid peptic diseases.

The dual focus on preparing for generic weight-loss drug ingredients and launching innovative molecules like Tegoprazan demonstrates Dr. Reddy's commitment to addressing diverse healthcare needs and maintaining its competitive edge in the global pharmaceutical landscape.

Dr Reddys Laboratories has announced the launch of Tegoprazan, a novel patented molecule for treating acid-related gastrointestinal diseases, in India under the brand name PCAB®. This launch marks a significant step in addressing the growing need for effective management strategies for acid peptic diseases (APD) in the country.

A Novel Approach to Acid-Related Gastrointestinal Diseases

Tegoprazan is a next-generation potassium-competitive acid blocker (P-CAB) indicated for the treatment of acid peptic diseases, including:

• Erosive Gastroesophageal Reflux Disease (GERD)
• Non-Erosive Gastroesophageal Reflux Disease (NERD)
• Gastric Ulcer

The drug is designed to induce a fast onset of action and control gastric pH for a prolonged period, potentially offering significant clinical benefits in APD management.

Addressing a Significant Market Need

Recent data indicates that APD affects approximately 38.00% of the Indian population, highlighting the widespread prevalence of these conditions. The launch of Tegoprazan by Dr. Reddy's aims to bridge the gap in treatment options for acid peptic diseases in India.

Impressive Clinical Trial Results

In a multinational clinical trial conducted by Dr. Reddy's across India, South Africa, and Russia, Tegoprazan demonstrated remarkable efficacy:

• 99.00% of GERD patients in the Tegoprazan treatment arm achieved endoscopic healing by Week 8

Global Presence and Future Prospects

Tegoprazan has already gained approval in 21 countries, including South Korea and China. The drug is currently under registration in several countries and has successfully completed Phase-III trials in the United States, indicating its potential for wider global adoption.

Strategic Partnership

The launch of Tegoprazan in India follows Dr. Reddy's exclusive partnership established in 2022 with South Korea-based HK inno.N Corporation. This collaboration aims to commercialize Tegoprazan in India and select emerging markets, leveraging the strengths of both companies to enhance patient access to this innovative molecule.

Management Perspectives

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) at Dr. Reddy's, expressed enthusiasm about the launch, stating, "We are happy to launch Tegoprazan (PCAB®) in India, reinforcing our commitment to innovation in gastrointestinal diseases treatment – a key focus area for us."

Dal-Won Kwak, Chief Executive Officer of HK inno.N Corporation, added, "We are confident that Tegoprazan will provide a valuable new treatment option for patients in India and contribute meaningfully to the improvement of gastrointestinal care."

Expanding the Gastrointestinal Portfolio

The introduction of Tegoprazan complements Dr. Reddy's existing portfolio of well-established brands in the gastrointestinal space, including Omez®, Razo®, and Vono™. This launch further solidifies the company's position in addressing critical gaps in acid peptic disease management and improving patient outcomes.

As Dr. Reddy's continues to focus on providing access to affordable and innovative medicines, the launch of Tegoprazan represents a significant milestone in their commitment to advancing gastrointestinal care in India and beyond.